- +852 4750 3485
- info@mycancerinfo.org
Colorectal cancer remains one of the most common malignancies worldwide and a leading cause of cancer-related mortality. While advances in targeted therapies have improved outcomes for some patients, treatment resistance and limited options for specific genetic subtypes continue to pose major challenges.
Recent research has identified a novel drug combination designed to target colorectal cancers with specific DNA repair-related mutations, offering a potential new strategy for patients with limited treatment options.
Colorectal cancer is a genetically diverse disease, with tumour behaviour often driven by specific molecular alterations.
One key subgroup involves tumours with defects in DNA damage response (DDR) pathways, such as mutations affecting ATM (ataxia-telangiectasia mutated), a protein critical for repairing DNA damage.
In these cancers:
Targeting such weaknesses is a central principle in modern precision oncology.
The newly identified approach combines:
This combination is designed to create a dual effect:
Together, this may lead to enhanced cancer cell death.
This strategy is based on a concept known as synthetic lethality:
As a result:
This targeted vulnerability may improve treatment selectivity.
The effectiveness of cancer treatment varies among each patient.
The drug combination demonstrated the ability to shrink colorectal tumours in preclinical and early clinical settings.
The approach showed promise in patients who had already undergone multiple prior treatments, a group with typically limited options.
The combination acts through complementary mechanisms—one inducing DNA damage and the other preventing repair—resulting in enhanced anti-tumour effects.
The treatment appears particularly relevant for patients with ATM-deficient tumours, suggesting a role for biomarker-driven therapy.
This research highlights several important trends in cancer care:
Therapies are increasingly tailored to specific tumour mutations rather than a one-size-fits-all approach.
Using drugs with complementary mechanisms may overcome resistance and enhance effectiveness.
Patients with heavily pretreated or resistant colorectal cancer may benefit from new targeted combinations.
While promising, further validation is required before widespread clinical adoption.
The development of a drug combination targeting DNA repair vulnerabilities represents a promising advance in colorectal cancer treatment.
By simultaneously inducing DNA damage and blocking repair mechanisms, this approach may offer a more effective strategy for selected patients, particularly those with ATM-related mutations.
More broadly, it reflects the ongoing shift toward precision oncology, where treatment is guided by the unique molecular profile of each tumour.
Precision medicine provides patients with clearer and more personalized treatment guidelines
Learn how precision medicine can help with your cancer treatment
The effectiveness of cancer treatment varies among each patient.
